JP2017532959A - Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム - Google Patents
Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム Download PDFInfo
- Publication number
- JP2017532959A JP2017532959A JP2017519013A JP2017519013A JP2017532959A JP 2017532959 A JP2017532959 A JP 2017532959A JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017532959 A JP2017532959 A JP 2017532959A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- mdm2i
- cancer
- tumor
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061992P | 2014-10-09 | 2014-10-09 | |
| US62/061,992 | 2014-10-09 | ||
| PCT/JP2015/079389 WO2016056673A1 (en) | 2014-10-09 | 2015-10-09 | Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017532959A true JP2017532959A (ja) | 2017-11-09 |
| JP2017532959A5 JP2017532959A5 (enExample) | 2018-11-22 |
Family
ID=54396934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519013A Withdrawn JP2017532959A (ja) | 2014-10-09 | 2015-10-09 | Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170283885A1 (enExample) |
| EP (1) | EP3204514A1 (enExample) |
| JP (1) | JP2017532959A (enExample) |
| WO (1) | WO2016056673A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CN104812384B (zh) | 2012-11-01 | 2020-09-18 | 爱勒让治疗公司 | 二取代的氨基酸及其制备和使用方法 |
| MX389354B (es) | 2014-09-24 | 2025-03-20 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y formulaciones de los mismos. |
| JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその使用 |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| CN109843329A (zh) * | 2016-10-17 | 2019-06-04 | 第一三共株式会社 | 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法 |
| CN107974502B (zh) * | 2016-10-19 | 2021-07-02 | 北京大学人民医院 | 一种用于同时检测nbpf10、tsfm、prb2及diaph1基因突变的试剂盒 |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| RU2747746C2 (ru) * | 2018-10-24 | 2021-05-13 | Общество с ограниченной ответственностью «Онкобокс» | Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| WO2021228814A1 (en) * | 2020-05-15 | 2021-11-18 | ETH Zürich | Mdm2 inhibitor response prediction method |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| WO2023009174A1 (en) * | 2021-07-30 | 2023-02-02 | Oregon Health & Science University | Methods for predicting lymph node status, likelihood of metastasis, and/or overall prognosis in patients with melanoma |
| CN118398086A (zh) * | 2024-04-19 | 2024-07-26 | 山东云海国创云计算装备产业创新中心有限公司 | 抗癌药物反应预测方法、装置、计算机设备及存储介质 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2380892B1 (en) * | 2009-01-16 | 2014-04-02 | Daiichi Sankyo Company, Limited | Imidazothiazole derivative having proline ring structure |
| SI2684880T1 (en) * | 2011-03-10 | 2018-08-31 | Daiichi Sankyo Company, Limited | DERIVAT DISPIROPYROLIDINE |
| US20120328692A1 (en) * | 2011-06-24 | 2012-12-27 | University Of Maryland, Baltimore | Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy |
| HUE045880T2 (hu) * | 2012-07-31 | 2020-01-28 | Novartis Ag | A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek |
| WO2014065760A1 (en) * | 2012-10-25 | 2014-05-01 | Agency For Science, Technology And Research | Methods for determining resistance against molecules targeting proteins |
| CA2912547A1 (en) * | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist |
-
2015
- 2015-10-09 US US15/510,892 patent/US20170283885A1/en not_active Abandoned
- 2015-10-09 EP EP15790296.6A patent/EP3204514A1/en not_active Withdrawn
- 2015-10-09 WO PCT/JP2015/079389 patent/WO2016056673A1/en not_active Ceased
- 2015-10-09 JP JP2017519013A patent/JP2017532959A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016056673A1 (en) | 2016-04-14 |
| EP3204514A1 (en) | 2017-08-16 |
| US20170283885A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532959A (ja) | Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム | |
| JP7128853B2 (ja) | ヘテロ接合性の消失(loss of heterozygosity)を評価するための方法および材料 | |
| JP2017508442A (ja) | Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー | |
| JP6246845B2 (ja) | 遺伝子発現を用いた前立腺癌の予後を定量化する方法 | |
| US11549148B2 (en) | Neuroendocrine tumors | |
| JP2022512080A (ja) | 次世代分子プロファイリング | |
| KR20230011905A (ko) | 파노믹 게놈 유병률 점수 | |
| KR20110111462A (ko) | 암 바이오마커 | |
| US20110165566A1 (en) | Methods of optimizing treatment of breast cancer | |
| WO2014071279A2 (en) | Gene fusions and alternatively spliced junctions associated with breast cancer | |
| JP2014509868A (ja) | 癌の予後のための遺伝子発現予測因子 | |
| KR20210124985A (ko) | 유사성 게놈 프로파일링 | |
| EP2785873A2 (en) | Methods of treating breast cancer with taxane therapy | |
| WO2015073949A1 (en) | Method of subtyping high-grade bladder cancer and uses thereof | |
| US20150240312A1 (en) | Copy number aberration driven endocrine response gene signature | |
| WO2016118670A1 (en) | Multigene expression assay for patient stratification in resected colorectal liver metastases | |
| WO2013079188A1 (en) | Methods for the diagnosis, the determination of the grade of a solid tumor and the prognosis of a subject suffering from cancer | |
| WO2014160080A1 (en) | Cancer diagnosis, treatment selection and treatment | |
| CN104212884B (zh) | 胰腺神经内分泌肿瘤易感基因位点及检测方法和试剂盒 | |
| US20170226592A1 (en) | Methods and kits used in classifying adrenocortical carcinoma | |
| Andres | A genomic approach for assessing clinical outcome of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181009 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181009 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20181203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181205 |